My Q3 Revenue Estimate: Should come in between
Post# of 405
Posted On: 10/30/2016 8:31:57 PM
My Q3 Revenue Estimate:
Should come in between $1.71 - 1.74M with 67% margins !!!
This would put us at just over $2.92M for the first 9 months of the year, needing a $2.1M Q4 to hit the stated guidance of $5M for all of 2016.
It is reasonable to assume that Q4 will be higher as it would have a FULL QTR worth of Recalmax sales as well as Sensum+ in the USA. Also, the favorable India ruling helps as well as more product sales would come out of that country.
** Keep on keepin on and please get the word out. NO DOWNSIDE to being a product ambassador for YOUR company
Note: 2017 guidance is 15M in Revenue and with Fluticare approval, jumps to $28-30M ! It is of my opinion, though, that in order to meet that range - approval needs to happen by end of November to allow company to distribute it ASAP / get it ready for sale in the new year.
Should come in between $1.71 - 1.74M with 67% margins !!!
This would put us at just over $2.92M for the first 9 months of the year, needing a $2.1M Q4 to hit the stated guidance of $5M for all of 2016.
It is reasonable to assume that Q4 will be higher as it would have a FULL QTR worth of Recalmax sales as well as Sensum+ in the USA. Also, the favorable India ruling helps as well as more product sales would come out of that country.
** Keep on keepin on and please get the word out. NO DOWNSIDE to being a product ambassador for YOUR company
Note: 2017 guidance is 15M in Revenue and with Fluticare approval, jumps to $28-30M ! It is of my opinion, though, that in order to meet that range - approval needs to happen by end of November to allow company to distribute it ASAP / get it ready for sale in the new year.
(1)
(0)Innovus Pharmaceuticals Inc. (INNV) Stock Research Links
Scroll down for more posts ▼